Showing results (91-100 of 111) with videos related to
Sort By:
Pageof 12
The Oncologist|June 2, 2021
Prognostic Role of Circulating Tumor Cells in Metastatic Renal Cell Carcinoma: A Large, Multicenter, Prospective TrialUmberto Basso, Antonella Facchinetti, Elisabetta Rossi, et al.Clinical Lung Cancer|July 30, 2025
The Italian Mauris Phase IIIb Trial of Atezolizumab Plus Carboplatin and Etoposide for Patients With Newly Diagnosed Extensive-Stage Small Cell Lung Cancer: 3-Year End-of-Study ResultsFloriana Morgillo, Ester Del Signore, Emilio Bria, et al.The Lancet. Oncology|May 17, 2014
Predictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): a biomarker-stratified, randomised phase 3 trialVanesa Gregorc, Silvia Novello, Chiara Lazzari, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2024
CONTACT-01: A Randomized Phase III Trial of Atezolizumab + Cabozantinib Versus Docetaxel for Metastatic Non-Small Cell Lung Cancer After a Checkpoint Inhibitor and ChemotherapyJoel Neal, Nick Pavlakis, Sang-We Kim, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 12, 2022
Efficacy of Brigatinib in Patients With Advanced ALK-Positive NSCLC Who Progressed on Alectinib or Ceritinib: ALK in Lung Cancer Trial of brigAtinib-2 (ALTA-2)Sai-Hong Ignatius Ou, Makoto Nishio, Myung-Ju Ahn, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 10, 2019
Efficacy and Safety of Ceritinib (450 mg/d or 600 mg/d) With Food Versus 750-mg/d Fasted in Patients With ALK Receptor Tyrosine Kinase (ALK)-Positive NSCLC: Primary Efficacy Results From the ASCEND-8 StudyByoung Chul Cho, Radka Obermannova, Alessandra Bearz, et al.The Lancet. Oncology|November 11, 2018
Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 studyBenjamin J Solomon, Benjamin Besse, Todd M Bauer, et al.Lung Cancer (Amsterdam, Netherlands)|April 5, 2016
BE-POSITIVE: Beyond progression after tyrosine kinase inhibitor in EGFR- positive non small cell lung cancer patients: Results from a multicenter Italian observational studyTiziana Vavalà, Alessandro Follador, Marcello Tiseo, et al.Clinical Lung Cancer|June 25, 2017
Outcomes of First-Generation EGFR-TKIs Against Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Post Hoc Analysis of the BE-POSITIVE StudySara Pilotto, Antonio Rossi, Tiziana Vavalà, et al.The Lancet. Oncology|April 2, 2026
Fulzerasib plus cetuximab in first-line KRASG12C-mutated non-small-cell lung cancer (KROCUS): a single-arm, multicentre, phase 1b/2 trialVanesa Gregorc, Margarita Majem, Giuseppe Lo Russo, et al.Pageof 12